Pinar Gumus Balikcioglu1, Metin Balikcioglu1, Michael J Muehlbauer1, Jonathan Q Purnell1, David Broadhurst1, Michael Freemark1, Andrea M Haqq1. 1. Division of Pediatric Endocrinology and Diabetes (P.G.B., M.F.), Duke University Medical Center, Durham, North Carolina 27710; Advanced Analytics (M.B.), SAS Institute Inc., Cary, North Carolina 27513; Duke Molecular Physiology Institute (M.J.M., M.F.), Sarah W. Stedman Nutrition and Metabolism Center, Duke University Medical Center, Durham, North Carolina 27710; Knight Cardiovascular Institute (J.Q.P.), Oregon Health & Science University, Portland, Oregon 97239; and Department of Medicine (D.B.) and Division of Pediatric Endocrinology and Diabetes (A.M.H.), University of Alberta, Edmonton, AB T6G 2R3 Canada.
Abstract
BACKGROUND: The roles of macronutrients and GH in the regulation of food intake in pediatric obesity and Prader-Willi Syndrome (PWS) are poorly understood. OBJECTIVE: We compared effects of high-carbohydrate (HC) and high-fat (HF) meals and GH therapy on ghrelin, insulin, peptide YY (PYY), and insulin sensitivity in children with PWS and body mass index (BMI) -matched obese controls (OCs). METHODS: In a randomized, crossover study, 14 PWS (median, 11.35 y; BMI z score [BMI-z], 2.15) and 14 OCs (median, 11.97 y; BMI-z, 2.35) receivedisocaloric breakfast meals (HC or HF) on separate days. Blood samples were drawn at baseline and every 30 minutes for 4 hours. Mixed linear models were adjusted for age, sex, and BMI-z. RESULTS: Relative to OCs, children with PWS had lower fasting insulin and higher fasting ghrelin and ghrelin/PYY. Ghrelin levels were higher in PWS across all postprandial time points (P < .0001). Carbohydrate was more potent than fat in suppressing ghrelin levels in PWS (P = .028); HC and HF were equipotent in OCs but less potent than in PWS (P = .011). The increase in PYY following HF was attenuated in PWS (P = .037); thus, postprandial ghrelin/PYY remained higher throughout. A lesser increase in insulin and lesser decrease in ghrelin were observed in GH-treated PWS patients than in untreated patients; PYY responses were comparable. CONCLUSION: Children with PWS have fasting and postprandial hyperghrelinemia and an attenuated PYY response to fat, yielding a high ghrelin/PYY ratio. GH therapy in PWS is associated with increased insulin sensitivity and lesser postprandial suppression of ghrelin. The ratio Ghrelin/PYY may be a novel marker of orexigenic drive.
RCT Entities:
BACKGROUND: The roles of macronutrients and GH in the regulation of food intake in pediatric obesity and Prader-Willi Syndrome (PWS) are poorly understood. OBJECTIVE: We compared effects of high-carbohydrate (HC) and high-fat (HF) meals and GH therapy on ghrelin, insulin, peptide YY (PYY), and insulin sensitivity in children with PWS and body mass index (BMI) -matched obese controls (OCs). METHODS: In a randomized, crossover study, 14 PWS (median, 11.35 y; BMI z score [BMI-z], 2.15) and 14 OCs (median, 11.97 y; BMI-z, 2.35) received isocaloric breakfast meals (HC or HF) on separate days. Blood samples were drawn at baseline and every 30 minutes for 4 hours. Mixed linear models were adjusted for age, sex, and BMI-z. RESULTS: Relative to OCs, children with PWS had lower fasting insulin and higher fasting ghrelin and ghrelin/PYY. Ghrelin levels were higher in PWS across all postprandial time points (P < .0001). Carbohydrate was more potent than fat in suppressing ghrelin levels in PWS (P = .028); HC and HF were equipotent in OCs but less potent than in PWS (P = .011). The increase in PYY following HF was attenuated in PWS (P = .037); thus, postprandial ghrelin/PYY remained higher throughout. A lesser increase in insulin and lesser decrease in ghrelin were observed in GH-treated PWSpatients than in untreated patients; PYY responses were comparable. CONCLUSION:Children with PWS have fasting and postprandial hyperghrelinemia and an attenuated PYY response to fat, yielding a high ghrelin/PYY ratio. GH therapy in PWS is associated with increased insulin sensitivity and lesser postprandial suppression of ghrelin. The ratio Ghrelin/PYY may be a novel marker of orexigenic drive.
Authors: M Angulo; M Castro-Magana; B Mazur; J A Canas; P M Vitollo; M Sarrantonio Journal: J Pediatr Endocrinol Metab Date: 1996 May-Jun Impact factor: 1.634
Authors: Anthony P Goldstone; Michael Patterson; Nila Kalingag; Mohammad A Ghatei; Audrey E Brynes; Stephen R Bloom; Ashley B Grossman; Márta Korbonits Journal: J Clin Endocrinol Metab Date: 2005-02-01 Impact factor: 5.958
Authors: Krystal A Irizarry; James Bain; Merlin G Butler; Olga Ilkayeva; Michael Muehlbauer; Andrea M Haqq; Michael Freemark Journal: Clin Endocrinol (Oxf) Date: 2015-04-01 Impact factor: 3.478
Authors: Andrea M Haqq; Diane D Stadler; Russell H Jackson; Ron G Rosenfeld; Jonathan Q Purnell; Stephen H LaFranchi Journal: J Clin Endocrinol Metab Date: 2003-05 Impact factor: 5.958
Authors: Rachel L Batterham; Mark A Cohen; Sandra M Ellis; Carel W Le Roux; Dominic J Withers; Gary S Frost; Mohammad A Ghatei; Stephen R Bloom Journal: N Engl J Med Date: 2003-09-04 Impact factor: 91.245
Authors: Krystal A Irizarry; Diana R Mager; Lucila Triador; Michael J Muehlbauer; Andrea M Haqq; Michael Freemark Journal: Clin Endocrinol (Oxf) Date: 2019-01-31 Impact factor: 3.478
Authors: Kirsten S de Fluiter; Gerthe F Kerkhof; Inge A L P van Beijsterveldt; Laura M Breij; Leonie C van Vark-van der Zee; Monique T Mulder; Marieke Abrahamse-Berkeveld; Anita C S Hokken-Koelega Journal: Eur J Nutr Date: 2021-03-25 Impact factor: 5.614
Authors: G Muscogiuri; L Barrea; F Faggiano; M I Maiorino; M Parrillo; G Pugliese; R M Ruggeri; E Scarano; S Savastano; A Colao Journal: J Endocrinol Invest Date: 2021-04-23 Impact factor: 4.256